ASX: CVB

05 February 2026

Euroz Hartleys 2026 Healthcare Forum Presentation

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, "CurveBeam AI" or the "Company"), a developer of point-of-care specialised medical imaging (CT) equipment and AI-enabled SaaS-based clinical assessment solutions, is pleased to announce it will be presenting today at the Euroz Hartleys 2026 Healthcare Forum. The presentation to be given today is attached herewith.

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non-weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to https://curvebeamai.com

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

CURVEBEAM AI (ASX: CVB) SLIDES

2026 EUROZ HARTLEYS HEALTHCARE FORUM

February 5th 2026

DISCLAIMER

Introduction

THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT, AND DOES NOT CONSTITUTE, AN OFFER OR INVITATION TO SUBSCRIBE FOR, BUY OR SELL SECURITIES IN ANY JURISDICTION. BY ACCEPTING, ACCESSING OR REVIEWING THIS PRESENTATION, YOU ACKNOWLEDGE AND AGREE TO THE TERMS SET OUT BELOW.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 5th February 2025. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other offering document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or the law of any other jurisdiction. It should be read in conjunction with CurveBeam's other periodic and continuous disclosure announcements, including its full year results for the period ended 30 June 2025, lodged with the ASX on 28 August 2025 available from the Australian Securities Exchange ("ASX") at www.asx.com.au.

As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees, recommends, or makes any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation or the Company's securities, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of or reliance on such information including as to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect to the subscription, purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.

The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). No representation, warranty or assurance (express or implied is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this Presentation may not be distributed or released in the United States. The entitlements and the New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which CurveBeam has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. Refer to the Appendix of this Presentation for further details about international offer restrictions

Financial information

All numbers in this presentation are stated in Australian dollars (**A$**) unless stated otherwise.

CORPORATE SNAPSHOT

Share Price	8.0 cents
Mkt Cap	~$36m
Recent Strategic Investment	40.5 cents
Cash at bank 31 Dec 2025	Proforma $8.0m
FY24 Sales	$6.5m
FY25 Sales (circa 90% growth)	$12.1m
Institutional shareholding	~50%
Strategic (Wego Orthopaedics)	5% (milestone based)
Directors, Employees & Related Parties	~27%



Substantial Shareholders	%
Firetrail Investments	11.25%
Arun Singh (Director)	10.8%
Ilwella	7.7%
Greg Brown (Director)	4.9%
Frazis	4.6%

CurveBeam AI

MEDICAL DEVICE COMPANY – CT SCANS

HiRise™ is a weight bearing CT scanner, a specialised CT scanner that lets doctors image a patient's bones and joints under normal standing load (not just lying down). This gives more accurate joint alignment & pathology information, particularly useful in orthopaedics, compared with traditional CT/MRI setups



- **FDA, CE & TGA are in place**
- **Compact, fast & clinic-friendly**
- **Standing & lying down capabilities**
- **200+ weight bearing CT (WBCT) Installations globally**
- **Tier One Commercial partners in Stryker Corp. & Wego Orthopaedics**

CurveBeam AI

THE PROBLEM

Traditional CT Scans don’t show the joint under it natural weight

Traditional CT Scan (i.e. non-weight bearing)	**HiRise™** CT Scan (i.e. weight bearing & non-weight bearing)



TRADITIONAL CT SCANNER



HIRISE™ SCANNER

Additional Challenges:

- ✖ Can be large and bulky pieces of equipment
- ✖ Requires referral out for scans, multiple visits
- ✖ Requires radiologist
- ✖ Requires shielded room (due to radiation)

Additional Benefits:

- ✓ Small enough to fit in a group surgeons’ practice
- ✓ Provides images under a person’s own body weight
- ✓ Can be run by X-ray staff, lower patient radiation dose per scan
- ✓ Improves surgeon patient workflow

CurveBeam AI

MORE THAN JUST A CT SCANNER

Unique AI SaaS capabilities that are IP protected

3D Software Capabilities

The HiRise™ is capable of providing 3D images:

- Automatic segmentation and separation (saves time & provides a more concise result)
- Creates 3D models & automated anatomical measurements



Superior Image for surgical planning

Superior 3D diagnostic image allows for:

- More precise cut guides & corrections
- Patient specific implants & better clinical review
- More informed alignment under weight

Automated Bone Density Testing

Superior 3D diagnostic image allows for:

- Realtime BMD assessment – e.g. Osteoporosis
- Today 1 week to 3 month waiting times
- More informed total joint replacement planning



Further Benefits

- ✓ **Quicker and easier to scan** than traditional CT and MRI, with faster image acquisition time
- ✓ **Small enough to fit into a surgeon's office** – unique compact design allows easier placements
- ✓ **Radiation dose lower** than traditional CT – up to 66% less than traditional CT

WORKFLOW FOR SURGEONS

Improved workflow speaks for itself

Typical US/European Workflow for Total Joint Replacement (TJR)

First visit to surgeon

Surgeon refers patient for CT imaging

Patient undergoes CT imaging

Radiologist *bills for scan*
~US$240-US$400 for scan

CT Scan sent to surgeon
1 -7 days

Second visit to surgeon

Surgeon refers patient for Bone Density imaging

Patient undergoes Bone Mineral Density (BMD) imaging

Radiologist *bills for scan*
~$140 for scan

BMD sent to surgeon
1 week – 2.5 months delay

Third visit to surgeon

Surgery Plan

US/European Workflow for TJR with HiRise™

First visit to surgeon

Surgeon has HiRise™ in their practice

Patient undergoes CT imaging & Bone Mineral Density (BMD) imaging on HiRise™

Surgeon targeted average *bill for scans*
~US$240-$400 for CT scan
&
~US$140 for BMD scan

Surgery Plan

Summary for typical TJR	Typical	With HiRise™
Patient Visits to Surgeon	3	1
CT Revenue to Radiologist	~US$250	~US$60
CT Revenue to Surgeon	$0	~US$190

******Surgeons are incentivised to adopt HiRise™******

CurveBeam AI

STRONG FOUNDATIONS TO COMMERCIALISE

Validated by studies, regulatory bodies and leading institutions

Clinically Validated

Over 100 published papers supporting WBCT benefits - HiRise™

Major Approvals Secured

FDA Cleared (US)
TGA Listed (Aust)
CE Marked (Europe)
Health Canada

Adopted by leading medical institutions - reimbursement

MAYO CLINIC

Hospital for Special Surgery HSS — #1 globally recognised specialist orthopaedic hospital in the US

Massachusetts General Hospital
Founding Member, Mass General Brigham

Duke Orthopaedics

Penn Medicine

Secured First Class Partners

stryker
- United States
- ~US$144b mkt cap
- One of the largest orthopaedic companies in the US

WEGO 威高
- Greater China
- Joint Venture
- One of the largest orthopaedic China players

CurveBeam AI

GLOBAL GROWTH STRATEGY

Successful placement of HiRise™ devices all around the world

NORTH AMERICA
Operations HQ (Penn.)
4 FTE Sales reps
Marketing Team
Partner Management (Stryker)
50 HiRise™ Placements

stryker

EUROPE
8 Distributors
3 FTE Sales reps
15 HiRise™ Placements

MENA
3 Distributors

Japan /ASIA
4 Distributors

SOUTH AMERICA
2 Distributors

AUSTRALIA
Corporate Office HQ
SE ASIA Mgt
Direct sales
2 HiRise™ Placements

stryker

WEGO ORTHO 威高骨科

GREATER CHINA
Partnership with WEGO
2 HiRise™ Placements



Over 65+ HiRise™ placements globally

CurveBeam AI

HIRISE™ ORDERS GAINING MOMENTUM

Strategy in-play to increase HiRise™ purchases



	FY2024				FY2025				FY2026	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Rest of world	1	3	6	11	2	4	7	10	0	0
United States	2	4	6	11	1	9	13	16	4	9

Strategy to increase HiRise™ Orders

- China Partnership - China FDA (NMPA)
- CVB Vendor Financing
- Validate Market Leading Robotic Device
- Expanding Distribution Partners
- Expanding High-Value SaaS Offering

CurveBeam AI

TARGETING GROUP SURGEON PRACTICES (US)

Practical benefits and new revenue stream ideal for surgeon practices

CURRENT PRACTICE

- Traditional CT Scanners are predominantly in hospitals or radiology clinics
- Can be large and chunky pieces of equipment
- Typically, a surgeon must refer out a patient to get a CT Scan:
  - ✖ Inconvenient for patient (patient has to travel to a new location to get a CT scan)
  - ✖ Timely (patients can be delayed by days or weeks to get a CT Scan)
  - ✖ Hospital or radiological clinic obtains revenue for CT Scan (surgeon gets nothing from scan)

INTRODUCING HIRISE™ INTO SURGEON PRACTICES

Introducing a HiRise™ (small enough to be placed in a surgeons' group practice) means:

- Patient does not have to travel to obtain a CT Scan
- Surgeon & patient can obtain CT Scan results within minutes at time of appointment
- Surgeon now obtains payment for the CT Scan → **New profit stream for surgeon**
- More convenient and efficient for surgeons as they manage the entire process





~5,800 orthopaedic group practices in the US

A$3.6bn Opportunity

CurveBeam AI

UNITED STATES STRATEGY

Partnership with stryker Foot and Ankle (F&A)

Key Points

- Stryker is one of the largest orthopaedic companies (Mkt Cap: ~US$144 billion)
- Agreement is with Foot & Ankle division of Stryker – 500 reps / 40 Regional Mgrs.
- Stryker currently selling into the United States & Australia/NZ
- ~17k potential installation sites in the US alone
- Sells the most successful CT-based robotic surgical system

Potential to significantly increase sales (Internal Vendor Validation)

- Stryker is going through an internal validation process to approve HiRise™ in conjunction with its market leading robotic device
- Should the validation process be successful, it will likely materially increase HiRise™ sales as the HiRise™ would be complimentary to Stryker's robotic device
- **An estimated US installed base of circa 2000 in 2026**

Economics of HiRise™ (US)

- Stryker sells HiRise™ for ~US$460,000
- CVB transfers HiRise™ for ~US$360,000
- CurveBeam AI aims for ~50% gross margin
- US Cat 1 CPT Code & NCD in place – pre-authorisations often needed

CurveBeam AI

GREATER CHINA MARKET OPPORTUNITY

Chinese Partner opens up ASIA and large addressable market

38,000 hospitals in China

- ✓ Facilitates rapid entry into one of the world's largest markets
- ✓ Volume-based manufacturing to deliver lower costs & greater margins (outside US)
- ✓ Unlocks new markets in ASIA, Middle East and Africa (previously uneconomical for the Company)
- ✓ US tariff mitigation, secures & diversifies supply chain

CurveBeam AI

GREATER CHINA STRATEGY[1]

Partnership with Shandong Weigao Haixing subsidiary of Wego Orthopaedics

WEGO ORTHO 威高骨科

Key terms

- For the sale, marketing, distribution, manufacturing, regulatory approval & IP for CVB's weight bearing CT & AI technology in China, Hong Kong, Macau & Taiwan (**Territories**)
- 10-year Exclusive licensing agreement for greater China
- JV Partner to make $10m equity investment in CVB:
  - 30-60 days of execution of license agreements - A$4 million
  - HiRise™ units sold generating ~A$4.6 million in sales - A$1 million
  - HiRise™ units generating ~A$23 million in sales - A$2 million
  - Regulatory & next generation US product release - A$1 million
  - SkyRise™& HiRise™ China manufacturing - A$2 million

Shares to be issued at a premium of $0.405 per share

Economics of HiRise™ (ASIA)

- JV Partner manufactures products
- JV Partner markets & sells products
  - ❑ US manufactured HiRise ™ initially
  - ❑ Then China manufactured HiRise ™
- CVB earns royalties based on China produced HiRise™ /SkyRise™ scanner for greater Chinese sales
- **Seeking China FDA Approval (MNPA)**

1. Full details in ASX Announcement dated 30 October 2025

CurveBeam AI

BUSINESS MODEL (US)

HiRise led entry into knee & hip group practices, with SaaS as the scalable revenue engine on high value tests (BMD)

CVB Business Model

Capital Equipment

Software as a Service (SaaS)

Capital Equipment

- ✓ Circa US$465,000 or A$715,000
- ✓ Typically, once-off large cash payments
- ✓ Targets 50% GP on transfer price
- ✓ Re-occurring revenue on maintenance of equipment – 10% of sale annually

Software as a Service (SaaS)

- ✓ Re-occurring revenue on annuity basis at attractive gross profit margins
- ✓ In the US we are targeting an annuity of around A$350,000 per unit targeting 90%+ GP
- ✓ For every 100 placements, this generates an ongoing target annuity of A$35m

COMPETITORS

Lacking a one size fits all approach

- Size of competitor devices not conducive to surgeon setting
- Many still are limited by multi detector computed tomography (MDCT) and the high-level radiation scans

Compact but non-natural weight bearing

PlanMed Verity

Example of Large CT Scanners

Canon Aquilion RISE

SinoVision

PlanMed XFI

Angel WR

✖ Requires shielded room & CT Technologists to perform scan

✖ Cone Beam CT limited by height restrictions, no dual lying down (non-weight bearing) option

CurveBeam AI

NEXT GENERATION WBCT SCANNER IN DEVELOPMENT

SKYRISE™

- Entire body CT Scan – covers spine & shoulder
- Entire CT Scan under natural body weight
- Small enough for surgeon practices
- First prototype targeting December 2026
- Developing with Strategic partner - WEGO

SKYRISE™
Next Generation Capability

NEAR TERM TARGETED MILESTONES

1	First License Payment from China Partner	Q4 CY25 ✓
2	MDCT Bone Mineral Density FDA filing	Q4 CY25 ✓
3	Bone Mineral Density (BMD) CT FDA clearance	H1 CY26
4	Chinese FDA (NMPA) approval for US manufactured HiRise™	H2 CY26
5	Internal validation from Stryker	Ongoing

CurveBeam AI

BOARD OF DIRECTORS

Experienced and personally invested Board

ROBERT LILLEY

Non-Executive Chairman, BA (Yale)

- 35 years' experience in medical device and diagnostics industry. Previously senior vice president of global sales and marketing, Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN)
- Currently Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company

GREGORY BROWN

Chief Executive Officer, B.app.Sc, MBA

- 35 years healthcare experience
- Previously Baxter Diagnostics (Australia & UK), Roche Molecular (Switzerland/New York), Digene Corp (Washington DC/Germany)
- 2006-2012 ImpediMed CEO (IPD:ASX)
- 2014 – 2022 StraxCorp (Chairman & CEO)
- Board experience: Trinity Biotech (NASDAQ), Immunexpress (IXP), IPD(ASX), UniQuest (UQ)

ARUN SINGH

Executive Director, COO, CTO-CT, US president

BSc & Masters Degree in Electrical Engineering

- Founder, President and CEO of CurveBeam LLC
- Led the development of the first commercially viable Cone Beam CT imaging system for dental and maxillofacial imaging, with 9,000+ systems deployed today globally
- Awarded Lifetime Achievement Award by the AADMRT in 2016 for his visionary contributions to the advancement of cone beam CT

HASHAN DE SILVA

Non-Executive Director,

BSc (Medicine), MCom, CFA charterholder

- Founder and Managing Partner of KP Rx, a specialist healthcare fund manager
- Previously head of healthcare research at Karst Peak Capital, equity research analyst in healthcare at CLSA Limited and Senior Research Associate Analyst at Macquarie Group
- Director Pharmaxis Limited (ASX:PXS)